OA22.01 STELLAR - Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma

Abstract

in the acute hospital before they died, with both length of stay and total bed days reduced by almost a third (comparisons with local data from 2012). Conclusion:A new model of proactive BSC in lung cancer has been successfully developed and piloted in NHS Fife. Patients and those close to them are now consistently supported from the point of diagnosis, with the impact of improved quality of care and more appropriate use of healthcare resources.

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study

“…High median compliance with the medical device was observed over the course of the first three months of TTFields treatment. In line with previous clinical trials investigating TTFields [18][19][20][21][22], skin toxicity was the only adverse event reported to be associated with the administration of TTFields. This toxicity is normally referred to as irritating contact dermatitis and is probably related to the chronic exposure of the epidermis to irritants, which are part of the transducer arrays (e.g.…”

“…Since TTFields act on phases of the mitotic process, which are common to all eukaryotic cells, they have the potential of targeting other cancers. Indeed, TTFields have been demonstrated to be effective in in vitro and in vivo models of pancreatic cancer, nonsmall-cell lung cancer, mesothelioma and other tumor types [19][20][21][22]. Encouraging results from pilot studies have led to ongoing phase 3 studies in non-small-cell lung cancer (NSCLC, NCT02973789), locallyadvanced pancreatic adenocarcinoma (NCT03377491) and brain metastasis from NSCLC (NCT02831959).…”

“…The layout of arrays is applied by the patient at home and maintained using a schematic illustration provided by the treating physician. Patients have used TTFields at home for at least 18 h per day and no serious systemic toxicities have been reported to be associated with the treatment [18][19][20][21][22]. TTFields were successfully tested in patients with newly diagnosed glioblastoma, leading to a significant prolongation of overall survival (OS) when given in combination with maintenance temozolomide [18].…”